|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel显示文摘 | Fausto Petrelli Karen Borgonovo Sandro Barni | 2010 | Expert Opinion on Pharmacotherapy2010，，8： | 1 |
| 2 | Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials显示文摘 | Fausto Petrelli Karen Borgonovo Mary Cabiddu Sandro Barni | 2012 | Clinical Lung Cancer2012，，2： | 1 |
| 3 | The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis显示文摘 | Fausto Petrelli Andrea Coinu Karen Borgonovo Mary Cabiddu Mara Ghilardi Veronica Lonati Sandro Barni | 2014 | Breast Cancer Research and Treatment2014，，2： | 1 |
| 4 | FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials显示文摘 | Fausto Petrelli Karen Borgonovo Mary Cabiddu Mara Ghilardi Veronica Lonati Federica Maspero Maria Grazia Sauta Giordano Domenico Beretta Sandro Barni | 2013 | Clinical Colorectal Cancer2013，，： | 1 |
| 5 | FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials显示文摘 | Giordano Domenico Beretta Fausto Petrelli Sergio Stinco Mary Cabiddu Mara Ghilardi Michela Squadroni Karen Borgonovo Sandro Barni | 2013 | Medical Oncology2013，，1： | 1 |
| 6 | Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials显示文摘BACKGROUND:Progression-free survival(PFS)has not been extensively investigated as a surrogate for survival in the firstline treatments of pancreatic cancer.The aim of this review was to evaluate PFS as a potential surrogate endpoint for overall survival(OS)in advanced pancreatic cancer in trials comparing poly-chemotherapy to gemcitabine alone. | Fausto Petrelli Andrea Coinu Karen Borgonovo Mary Cabiddu Sandro Barni | 2015 | Hepatobiliary & Pancreatic Diseases International2015，14，2： | 1 |
| 7 | Which strategy after first-line therapy in advanced colorectal cancer?显示文摘Second-line therapy for advanced colorectal cancer is an integral part of the treatment strategy that needs to be set from the beginning for each patient, bearing in mind the expected toxicities of chosen treatments, the patient's clinical condition, comorbidities, preferences, the aims of the treatment and the molecular status. Furthermore, the distinction between lines of therapy is no longer absolute. The perspective of 'continuum of care' includes switching chemotherapy prior to disease progression, maintenance therapy, drug 'holidays' if needed, surgical resection of metastases in selected patients, and seems to allow a tailored treatment, in which patients are more likely to benefit from exposure to all active agents, which is known to correlate with overall survival. The scenario of second-line treatment has changed dramatically over the years and could currently benefit from several options including chemotherapy with a single agent or in combination and the addition of molecular-targeted agents developed in the last decade, such as epidermal growth factor receptor antibodies(cetuximab, panitumumab) and vascular endothelial growth factor-targeting agents(bevacizumab, aflibercept), with the possibility of bevacizumab use even beyond first progression. The purpose of this review is to summarize the most important scientific data supporting the use of chemotherapy and the new biologic agents in the second-line setting in advanced colorectal cancer. | Coinu Andrea Petrelli Fausto Borgonovo Karen Francesca Cabiddu Mary Ghilardi Mara Lonati Veronica Barni Sandro | 2014 | World Journal of Gastroenterology2014，20，27： | 1 |
| 8 | Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies显示文摘 | Fausto Petrelli Karen Borgonovo Mary Cabiddu Mara Ghilardi Sandro Barni | 2012 | Expert Opinion on Drug Safety2012，，1： | 1 |
| 9 | First-line pazopanib in patients with advanced non-clear cell renal carcinoma:An Italian case series显示文摘BACKGROUND Non-clear cell(ncc)metastatic renal-cell carcinoma(RCC)has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart.New systemic combination therapies have emerged for metastatic RCC(mRCC),but the pivotal phase III trials excluded patients with nccRCC,which constitute about 30%of metastatic RCC cases.AIM To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.METHODS The present study is a multicenter retrospective observational analysis aiming to assess the activity,efficacy,and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.RESULTS Overall,48 patients were included.At the median follow-up of 40.6 mo,the objective response rate was 27.1%,the disease control rate was 83.3%,and the median progression-free survival and overall survival were 12.3(95%confidence interval[CI]:3.6-20.9)and 27.7(95%CI:18.2-37.1)mo,respectively.Grade 3 adverse events occurred in 20%of patients,and no grade 4 or 5 toxicities were found.CONCLUSION Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology. | Sebastiano Buti Melissa Bersanelli Francesco Massari Ugo De Giorgi Orazio Caffo Gaetano Aurilio Umberto Basso Giacomo Carteni Claudia Caserta Luca Galli Francesco Boccardo Giuseppe Procopio Gaetano Facchini Giuseppe Fornarini Alfredo Berruti Elena Fea Emanuele Naglieri Fausto Petrelli Roberto Iacovelli Camillo Porta Alessandra Mosca | 2021 | World Journal of Clinical Oncology2021，12，11： | 0 |
| 10 | Tocilizumab as treatment for COVID-19:A systematic review and meta-analysis显示文摘BACKGROUNDThe majority of patients with coronavirus disease 2019 (COVID-19) have goodprognoses, but some develop a critical illness that can lead to death. Evidenceshows severe acute respiratory syndrome is closely related to the inducedcytokine storm. Interleukin-6 is a key player;its role in systemic inflammation iswell known.AIMTo evaluate the effect of tocilizumab (TCZ), an interleukin-6 receptor antagonist,on the outcomes for patients with COVID-19 pneumonia.METHODSPubMed, EMBASE, SCOPUS, Web of Science, MedRxiv, Science Direct, and theCochrane Library were searched from inception to 9th June 2020 for observationalor prospective studies reporting results of hospitalized adult patients withCOVID-19 infection treated with TCZ. Effect sizes were reported as odds ratios(ORs) with 95% confidence intervals (CIs), and an OR less than 1 was associatedwith a better outcome in those treated with TCZ.RESULTSOverall 13476 patients (33 studies;n = 3264 received TCZ) with COVID-19pneumonia and various degree of severity were included. Outcome wasimproved with TCZ. In the primary analysis (n = 19 studies reporting data),mortality was reduced in patients treated with TCZ (OR = 0.64, 95%CI: 0.47-0.87;P < 0.01). In 9 studies where risk of death with TCZ use was controlled for othervariables mortality was reduced by 57% (OR = 0.43, 95%CI: 0.27-0.7;P < 0.01).Intensive care need (mechanical ventilation) was also reduced (OR = 0.36, 95%CI:0.14-0.89;P = 0.02).CONCLUSIONIn COVID-19-infected patients treated with TCZ, outcome may be improvedcompared to those not treated with TCZ. | Fausto Petrelli Sara Cherri Michele Ghidini Gianluca Perego Antonio Ghidini Alberto Zaniboni | 2021 | World Journal of Methodology2021，11，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员